You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

iBRUtinib

( eye-BROO-tih-nib )
Funding:
Exceptional Access Program
  • iBRUtinib - For patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), according to specific criteria.
  • iBRUtinib - For relapsed and refractory Mantle Cell Lymphoma, according to clinical criteria
Other Name(s): Imbruvica®
Appearance: capsule

Patient Info Sheet

Apr 2017

What it is used for

• For treating blood cancers such as chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL) and Waldenström's macroglobulinemia (WM).



You might also be interested in